Key Highlights

  • ILMN shares trade 14.12% lower today at $249.09, implying a prior close near $290.
  • Third-quarter results were scheduled for Oct. 29, with consensus at $1.36 per share and $1.15 billion in revenue.
  • Second-quarter profit reached $1.31 per share, ahead of the $1.23 consensus, while Revenue hit $1.16 billion.
  • The July outlook called for full-year Earnings of $5.30 to $5.40 per share.
  • The 52-week span ran from $94.00 to $309.35 as of Oct. 26, and market Capitalization was $40.93 billion.

Shares Fall From Above $290 in the Session After the Scheduled Third-Quarter Release

Illumina (NASDAQ:ILMN) stock is down 14.12% today at $249.09, which points to a previous close of about $290. The company had set its third-quarter 2026 results for Thursday, Oct. 29. Neither the specific numbers nor any guidance change linked to today's decline could be verified from the sources reviewed, so the trigger remains unstated.

Ahead of the release, market estimates expected $1.36 per share in earnings and $1.15 billion in revenue. The stock had finished at $271.04 on Oct. 26, a gain of roughly 0.6% for that session, and its 52-week peak stood at $309.35.

A Second-Quarter Beat and $5.30 to $5.40 Guidance Framed the Expectations

In its July 30 report, Illumina delivered second-quarter earnings of $1.31 per share versus a $1.23 consensus. Revenue reached $1.16 billion compared with $1.13 billion expected. Full-year earnings guidance was set at $5.30 to $5.40 per share, and trailing twelve-month revenue came to $4.49 billion, up 4.9%.

The Business supplies DNA sequencing and array tools and has been widening its software offering. On Oct. 14 it introduced the BioInsight Platform for genomic and multiomic data, and about a week later DRAGEN Ultra software became available in early access. An unsecured Commercial Paper program of up to $1.0 billion was also put in place.

A Stephens Downgrade and a 50.47 Times Trailing Earnings Multiple Preceded the Slide

A $275 price target came with Stephens' move to Equal Weight from Overweight, which took place around Oct. 24. Illumina was taken off Evercore's Core Ideas list. Canaccord's target rose to $300 from $205, while Bank of America stayed at Underperform with a $168 target. Among 21 analysts, the consensus was Hold and the average target stood at $248.90.

At $271.04, the shares were valued at a trailing price-to-earnings ratio of 50.47 and a forward ratio of 47.58. The 52-week low of $94.00 underscores how much the shares had climbed before today's decline. These readings predate the latest fall.

Shares were volatile heading into the report. They climbed 5.57% to $282.86 on Oct. 21, then dropped 4.76% to $269.40 the next day and held near $270 through Oct. 26. Bank of America had raised its target to $168 around Oct. 10 but kept the Underperform rating, which left that objective well beneath the Market Price at the time.

Third-Quarter Figures and BioInsight Adoption Are What Comes Next

Today's decline wipes out a large portion of the recent rally, and the shares now sit close to the $248.90 average analyst target. The Oct. 29 results announcement and the quarterly filing should shed light on revenue, margins and any revision to full-year earnings guidance. Investors will also watch early uptake of the BioInsight Platform and whether analysts adjust targets after the report. First-quarter and second-quarter trends, including second-quarter revenue of $1.16 billion, offer a benchmark for comparison.